{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-258372","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2026-06-05T11:12:49+00:00","discovered_at":"2026-06-05T11:15:01.607916+00:00","generated_at":"2026-06-05T11:15:09.066251+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Climb Bio reports positive Phase 1 safety data for CLYM116; plans Phase 2 in IgAN in Q3 2026","bullets":["Translational PK/PD model from NHP data projects dose-dependent IgA suppression, suggesting less-frequent dosing.","Preliminary safety from 49 healthy volunteers (single doses up to 320 mg): no SAEs, DLTs, or discontinuations; all AEs mild-moderate and transient.","Partner Mabworks to initiate Phase 2 dosing in IgAN patients in Q3 2026 in China.","Company plans to advance CLYM116 into further clinical development based on data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-258372","json":"https://secwatch.observer/filing/0001193125-26-258372.json","markdown":"https://secwatch.observer/filing/0001193125-26-258372.md","text":"https://secwatch.observer/filing/0001193125-26-258372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526258372/0001193125-26-258372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526258372/d132290d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:15:09.066251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}